Investing.com -- Atara Biotherapeutics Inc (NASDAQ:ATRA)股价在美国食品药品监督管理局(FDA)接受其tabelecleucel(tab-cel)生物制品许可申请(BLA)的申报后上涨7%。 该BLA申请是为了将tab-cel作为单一疗法用于2岁及以上已接受至少一次先前治疗的EB病毒阳性移植后淋巴增殖性疾病(EBV+ PTLD)的成人和儿科...
Source LinkInvesting.com -- Atara Biotherapeutics Inc (NASDAQ:ATRA)股价在美国食品药品监督管理局(FDA)接受其tabelecleucel(tab-cel)生物制品许可申请(BLA)的申报后上涨7%。 该BLA申请是为了将tab-cel作为单一疗法用于2岁及以上已接受至少一次先前治疗的EB病毒阳性移植后淋巴增殖性疾病(EBV+ PTLD)的成人和儿科...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.